CD274 and neoplasm: PD-L1 was also assessed by flow cytometry since, in the late disease setting, TNBC tumors with high PD-L1 expression are more likely to benefit from ICI, though it has been reported that most of the PD-L1 is produced by stromal cells and not the tumor cells [37].